Evaluation of hypereosinophilia in a case of FLT3-mutant acute myeloid leukemia treated with gilteritinib

Acute myeloid leukemias (AMLs) frequently harbor activating mutations in Fms-like tyrosine kinase 3 (FLT3). The use of FLT3 inhibitors (FLT3i) is the standard of care for treatment of newly diagnosed and relapsed patients with AML. Differentiation responses including clinical differentiation syndrom...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Gutierrez, Leslie N., Burgher, Blake C., Glynias, Manuel J., Alvarado, Daniel, Griffiths, Elizabeth A., Glenn, Sean T., Sung, Pamela J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2023
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393187/
https://www.ncbi.nlm.nih.gov/pubmed/37433680
http://dx.doi.org/10.1101/mcs.a006279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393187/
https://www.ncbi.nlm.nih.gov/pubmed/37433680
http://dx.doi.org/10.1101/mcs.a006279

Ejemplares similares